gp100/HLA-A02 × CD3 × Albumin Trispecific TCR-Mimic Antibody

• Aliases:
• gp100: PMEL, ME20, ME20-M, ME20M, PMEL17, SILV; Albumin: ALB
• Modality:
• TCR-Mimic (TCRm) Antibody / T Cell Engager (TCE)
• Development Stage:
• Preclinical
• Indications:
• HLA-A*02:01⁺ metastatic uveal melanoma (mUM)
• Key Differentiation:
• A fully human trispecific TCE integrating gp100/HLA-A*02:01 recognition, CD3-mediated T-cell engagement, and an albumin-binding VHH, with preclinical data supporting controlled IFN-γ release, sustained T-cell fitness, prolonged systemic exposure, and durable antitumor activity.
• Partnership Opportunity:
• Available for licensing and co-development